These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32139177)

  • 1. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
    Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
    Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
    Wang PW; Liu RT; Tung SC; Chien WY; Lu YC; Chen CH; Kuo MC; Hsieh JR; Wang ST
    J Formos Med Assoc; 1998 Sep; 97(9):619-25. PubMed ID: 9795530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Two-Year Results of Using Radiofrequency Ablation as a Novel Treatment for Persistent or Relapsed Graves' Disease: A Prospective Study.
    Fung MHM; Luk Y; Yuen KKW; Lang BHH
    Thyroid; 2024 Aug; 34(8):1017-1026. PubMed ID: 38836419
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Anti-Thyroid Medications in Patients with Graves' Disease.
    Mahzari MM; Alanazi MM; Alabdulkareem YM; Alharbi WA; Alzahrani AS; Alqahtani NA; Ajwah IM; Ardah HI
    BMC Endocr Disord; 2024 Sep; 24(1):180. PubMed ID: 39237901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
    Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
    Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.
    Masiello E; Veronesi G; Gallo D; Premoli P; Bianconi E; Rosetti S; Cusini C; Sabatino J; Ippolito S; Piantanida E; Tanda ML; Chiovato L; Wiersinga WM; Bartalena L
    J Endocrinol Invest; 2018 Dec; 41(12):1425-1432. PubMed ID: 29946800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
    Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
    Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
    [No Abstract]   [Full Text] [Related]  

  • 10. Prediction for recurrence following antithyroid drug therapy for Graves' hyperthyroidism.
    Weng H; Tian WB; Xiao ZD; Xu L
    Arch Endocrinol Metab; 2023 May; 67(4):e000609. PubMed ID: 37252698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High neutrophil-to-lymphocyte ratio is associated with relapse in Graves' disease after antithyroid drug therapy.
    Kim M; Kim BH; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Kim IJ
    Endocrine; 2020 Feb; 67(2):406-411. PubMed ID: 31749116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the medical treatment of Graves' disease (GD)].
    Peixoto MC; Coeli CM; Vaisman M
    Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
    Park S; Song E; Oh HS; Kim M; Jeon MJ; Kim WG; Kim TY; Shong YK; Kim DM; Kim WB
    Endocrine; 2019 Aug; 65(2):348-356. PubMed ID: 31236779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
    Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
    Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.
    Vigone MC; Peroni E; Di Frenna M; Mora S; Barera G; Weber G
    J Endocrinol Invest; 2020 May; 43(5):595-600. PubMed ID: 31713721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X; Shi B; Li H
    Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of treatments for Graves disease in the children and adolescent population.
    Jawwad M; Ahmed SA; Zaidi SMM; Fatmi SAA; Ashraf MH; Naeem S; Chola MS
    Endocrine; 2023 Aug; 81(2):223-230. PubMed ID: 37115377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
    Rotondi M; Cappelli C; Pirali B; Pirola I; Magri F; Fonte R; Castellano M; Rosei EA; Chiovato L
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3985-8. PubMed ID: 18664537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
    Fung MHM; Lang BHH
    Eur Radiol; 2023 Sep; 33(9):6534-6544. PubMed ID: 37036479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.